financetom
Business
financetom
/
Business
/
Universal Technical Institute Fiscal Q2 Earnings, Revenue Rise; 2025 Guidance Increased
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Universal Technical Institute Fiscal Q2 Earnings, Revenue Rise; 2025 Guidance Increased
May 26, 2025 3:49 AM

04:58 AM EDT, 05/08/2025 (MT Newswires) -- Universal Technical Institute ( UTI ) reported fiscal Q2 earnings late Wednesday of $0.21 per diluted share, up from $0.14 a year earlier.

Analysts polled by FactSet expected $0.12.

Revenue for the quarter ended March 31 was $207.4 million compared with $184.2 million a year earlier.

Analysts surveyed by FactSet expected $196.6 million.

The company raised its 2025 earnings guidance to $1 to $1.08 per diluted share from $0.96 to $1.04. Analysts surveyed by FactSet expect $1.02. The company also increased its annual revenue guidance to $825 million to $835 million from $810 million to $820 million. Analysts polled by FactSet expect $819.4 million.

Universal Technical shares were up 7.5% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Maiden Holdings to Divest Swedish Subsidiaries in All-Cash Deal
Maiden Holdings to Divest Swedish Subsidiaries in All-Cash Deal
Dec 17, 2024
09:03 AM EST, 12/17/2024 (MT Newswires) -- Maiden Holdings ( MHLA ) said Tuesday it has agreed to sell its Swedish subsidiaries, Maiden General Forsakrings and Maiden Life Forsakrings, to an unnamed London-based buyer. The all-cash deal is subject to regulatory approval and includes the transfer of all staff and independent directors of the subsidiaries to the new ownership group,...
Gilead Sciences' Trodelvy Granted FDA Breakthrough Designation for Treating Extensive-Stage Small Cell Lung Cancer
Gilead Sciences' Trodelvy Granted FDA Breakthrough Designation for Treating Extensive-Stage Small Cell Lung Cancer
Dec 17, 2024
09:01 AM EST, 12/17/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday that its antibody-drug conjugate Trodelvy was granted US Food and Drug Administration breakthrough therapy designation for the treatment of adults with extensive-stage small cell lung cancer whose disease has progressed on or following platinum-based chemotherapy. The designation, which speeds up the FDA approval process, was based...
Rocket Lab USA Says It Delivered Second Spacecraft for Varda
Rocket Lab USA Says It Delivered Second Spacecraft for Varda
Dec 17, 2024
09:02 AM EST, 12/17/2024 (MT Newswires) -- Rocket Lab USA ( RKLB ) said Tuesday it delivered a second spacecraft to Vandenberg Space Force Base and completed production of a third for Varda Space Industries under a four-spacecraft contract supporting in-orbit pharmaceutical manufacturing and reentry operations. The company said the Pioneer spacecraft, built by Rocket Lab, supports Varda's capsule, which...
New HIV prevention drug could reach poorest countries by 2025, says health official
New HIV prevention drug could reach poorest countries by 2025, says health official
Dec 17, 2024
LONDON, Dec 17 (Reuters) - A new long-acting preventive HIV drug could reach the world's poorest countries by the end of 2025 or early 2026, a global health official told Reuters on Tuesday. The ambition is to start deliveries of Gilead Sciences' ( GILD ) lenacapavir on that timeline, said Hui Yang, head of supply operations at the Global Fund...
Copyright 2023-2026 - www.financetom.com All Rights Reserved